Eli Lilly and Co. terminated its AIR Insulin development program with partner Alkermes, Inc. The program has been in Phase III development as a potential treatment for type 1 and type 2 diabetes. According to the company, the decision is not related to the safety of the product, but due to regulatory concerns and the commercial potential of the product compared to existing therapies.     “This decision, though difficult, is the right one to make at this time,” commented John Lechl...